Last reviewed · How we verify
Stem Cell
Stem cell therapy aims to replace or repair damaged neural tissue by transplanting undifferentiated cells that can differentiate into functional neurons and glial cells.
Stem cell therapy aims to replace or repair damaged neural tissue by transplanting undifferentiated cells that can differentiate into functional neurons and glial cells. Used for Spinal cord injury, Neurological disorders (specific indications not clearly defined in public literature).
At a glance
| Generic name | Stem Cell |
|---|---|
| Also known as | PRP, - Edessy Stem cell Score., - Laparoscopic stem cell transplantation., - Hormonal Analysis, - Ultrasonic evaluation |
| Sponsor | Neurogen Brain and Spine Institute |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Stem cells, typically derived from bone marrow or other sources, are administered to sites of spinal cord injury or neurological damage where they can differentiate into replacement neurons and supporting glial cells, potentially restoring lost neural function. The mechanism may also involve paracrine effects, including anti-inflammatory signaling and promotion of endogenous repair pathways. This approach is intended to restore motor and sensory function in patients with spinal cord injuries or degenerative neurological conditions.
Approved indications
- Spinal cord injury
- Neurological disorders (specific indications not clearly defined in public literature)
Common side effects
- Infection at injection site
- Pain or discomfort at injection site
- Immune response or rejection
Key clinical trials
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Quality of Life in Patients Who Have Undergone Stem Cell Transplant
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |